logo
  

H.B. Fuller Profit Misses Estimates; Cuts FY Guidance

Adhesives and sealants maker H.B. Fuller Co (FUL) on Wednesday reported second-quarter net earnings of $24.6 million or $0.48 per share compared with $20.5 million or $0.40 per share last year.

Excluding items, adjusted earnings for the quarter were $0.63 per share compared with $0.78 per share a year ago.

The company said the negative impacts of a stronger US dollar and a higher core tax rate hurt adjusted earnings.

Revenues for the quarter were $540.8 million compared with $544 million in the prior year.

Analysts polled by Thomson Reuters estimated earnings of $0.66 per share on revenues of $555.2 million for the quarter. Analysts' estimates typically exclude special items.

For the full year 2015, the company now expects adjusted earnings of $2.45 per share on revenues of $2.1 billion. Earlier it expected earnings of $2.60 per share on revenues of $2.15 billion.

Analysts expect earnings of $2.54 per share on revenues of $2.16 billion for the year.

The company said its revised earnings guidance for 2015 reflects an expected increase in core tax rate.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT